Cargando…

Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), especially nonalcoholic steatohepatitis (NASH) increases the risk for liver cirrhosis. Noninvasive tests for NAFLD/NASH exist, but they are unreliable and thus liver biopsy remains the standard for diagnosis and new noninvasive diagnostic approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jonas, Kumar, Yogesh, Lautenbach, Anne, von Kroge, Philipp, Wolter, Stefan, Mann, Oliver, Izbicki, Jakob, Gagliani, Nicola, Duprée, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817352/
https://www.ncbi.nlm.nih.gov/pubmed/36609276
http://dx.doi.org/10.1186/s12944-022-01764-1
_version_ 1784864736061423616
author Wagner, Jonas
Kumar, Yogesh
Lautenbach, Anne
von Kroge, Philipp
Wolter, Stefan
Mann, Oliver
Izbicki, Jakob
Gagliani, Nicola
Duprée, Anna
author_facet Wagner, Jonas
Kumar, Yogesh
Lautenbach, Anne
von Kroge, Philipp
Wolter, Stefan
Mann, Oliver
Izbicki, Jakob
Gagliani, Nicola
Duprée, Anna
author_sort Wagner, Jonas
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), especially nonalcoholic steatohepatitis (NASH) increases the risk for liver cirrhosis. Noninvasive tests for NAFLD/NASH exist, but they are unreliable and thus liver biopsy remains the standard for diagnosis and new noninvasive diagnostic approaches are of great interest. The aim of this study was to test whether the serum levels of fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) could be used as a diagnostic tool for NASH. METHODS: Patients who underwent bariatric surgery and simultaneous liver biopsy were identified. Biopsies were assigned a NAFLD activity score (NAS). MMP9- and FABP4- Enzyme-linked Immunosorbent Assays (ELISAs) on serum samples were performed. The serum levels of FABP4/MMP9 were compared and different models to predict NASH were developed. RESULTS: A total of 84 patients were included, 28 patients (33.3%) were diagnosed with NASH. Higher concentrations of MMP9 in NASH patients (p < 0.01) were detected. FABP4 concentrations were not significantly increased. A moderate correlation between the NAS and MMP9 concentrations (r = 0.32, P < 0.01) was observed. The neural network model fit best with the dataset, with an area under the curve (AUC) of 83% and an accuracy of 88%. CONCLUSION: Serum MMP9 levels are increased in patients with NASH and should routinely be measured in patients with obesity, but further investigations are needed to improve noninvasive NASH diagnosis.
format Online
Article
Text
id pubmed-9817352
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98173522023-01-07 Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH) Wagner, Jonas Kumar, Yogesh Lautenbach, Anne von Kroge, Philipp Wolter, Stefan Mann, Oliver Izbicki, Jakob Gagliani, Nicola Duprée, Anna Lipids Health Dis Research BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), especially nonalcoholic steatohepatitis (NASH) increases the risk for liver cirrhosis. Noninvasive tests for NAFLD/NASH exist, but they are unreliable and thus liver biopsy remains the standard for diagnosis and new noninvasive diagnostic approaches are of great interest. The aim of this study was to test whether the serum levels of fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) could be used as a diagnostic tool for NASH. METHODS: Patients who underwent bariatric surgery and simultaneous liver biopsy were identified. Biopsies were assigned a NAFLD activity score (NAS). MMP9- and FABP4- Enzyme-linked Immunosorbent Assays (ELISAs) on serum samples were performed. The serum levels of FABP4/MMP9 were compared and different models to predict NASH were developed. RESULTS: A total of 84 patients were included, 28 patients (33.3%) were diagnosed with NASH. Higher concentrations of MMP9 in NASH patients (p < 0.01) were detected. FABP4 concentrations were not significantly increased. A moderate correlation between the NAS and MMP9 concentrations (r = 0.32, P < 0.01) was observed. The neural network model fit best with the dataset, with an area under the curve (AUC) of 83% and an accuracy of 88%. CONCLUSION: Serum MMP9 levels are increased in patients with NASH and should routinely be measured in patients with obesity, but further investigations are needed to improve noninvasive NASH diagnosis. BioMed Central 2023-01-06 /pmc/articles/PMC9817352/ /pubmed/36609276 http://dx.doi.org/10.1186/s12944-022-01764-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wagner, Jonas
Kumar, Yogesh
Lautenbach, Anne
von Kroge, Philipp
Wolter, Stefan
Mann, Oliver
Izbicki, Jakob
Gagliani, Nicola
Duprée, Anna
Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title_full Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title_fullStr Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title_full_unstemmed Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title_short Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
title_sort fatty acid-binding protein-4 (fabp4) and matrix metalloproteinase-9 (mmp9) as predictive values for nonalcoholic steatohepatitis (nash)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817352/
https://www.ncbi.nlm.nih.gov/pubmed/36609276
http://dx.doi.org/10.1186/s12944-022-01764-1
work_keys_str_mv AT wagnerjonas fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT kumaryogesh fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT lautenbachanne fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT vonkrogephilipp fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT wolterstefan fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT mannoliver fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT izbickijakob fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT gaglianinicola fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash
AT dupreeanna fattyacidbindingprotein4fabp4andmatrixmetalloproteinase9mmp9aspredictivevaluesfornonalcoholicsteatohepatitisnash